David Rolfe’s Bristol-Myers Squibb BMY Stock Holding History

David Rolfe’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,175	Closed	-$300K	–	38
2022 Q4	$300K	Sell	4,175 -1,250	-23%	-$94.3K	0.06%	36
2022 Q3	$385K	Sell	5,425 -500	-8%	-$36.3K	0.07%	33
2022 Q2	$456K	Sell	5,925 -1,000	-14%	-$76.2K	0.08%	33
2022 Q1	$505K	Buy	6,925 +2,250	+48%	+$151K	0.07%	32
2021 Q4	$291K	Sell	4,675 -625	-12%	-$36.7K	0.04%	36
2021 Q3	$313K	Sell	5,300 -325	-6%	-$21.4K	0.04%	36
2021 Q2	$375K	Sell	5,625 -70,210	-93%	-$4.58M	0.05%	36
2021 Q1	$4.79M	Sell	75,835 -338,222	-82%	-$21M	0.74%	23
2020 Q4	$25.7M	Sell	414,057 -25,262	-6%	-$1.55M	3.82%	15
2020 Q3	$26.5M	Buy	439,319 +65,538	+18%	+$3.94M	4.19%	12
2020 Q2	$22M	Buy	373,781 +114,601	+44%	+$6.85M	3.72%	12
2020 Q1	$14.4M	Sell	259,180 -132,262	-34%	-$8.08M	2.74%	16
2019 Q4	$25.1M	Buy	+391,442	New	+$22.4M	2.55%	17

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

David Rolfe's BMY Position: Q1 2023 in Review

David Rolfe sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 4,175 shares — an estimated $300K sold.

David Rolfe first reported a position in BMY in Q4 2019 and held it in 13 quarters. The position peaked at $26.5M in Q3 2020. 2,542 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

David Rolfe reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
David Rolfe sold 4,175 Bristol-Myers Squibb shares in Q1 2023, an estimated $300K.
David Rolfe first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 13 quarters.
David Rolfe's Bristol-Myers Squibb position peaked at $26.5M in Q3 2020.
2,542 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Wedgewood Partners's 13F filing for Q1 2023, filed 15 May 2023.